Stocks & Investing
Stocks and Investing
Stocks and Investing
Wed, September 8, 2021
[ Wed, Sep 08th 2021
] - WOPRAI
[ Wed, Sep 08th 2021
] - WOPRAI
[ Wed, Sep 08th 2021
] - WOPRAI
[ Wed, Sep 08th 2021
] - WOPRAI
[ Wed, Sep 08th 2021
] - WOPRAI
Tue, September 7, 2021
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
[ Tue, Sep 07th 2021
] - WOPRAI
Jonathan Chang Maintained (ADAP) at Hold with Increased Target to $6 on, Sep 7th, 2021
Jonathan Chang of SVB Leerink, Maintained "Adaptimmune Therapeutics plc" (ADAP) at Hold with Increased Target from $5 to $6 on, Sep 7th, 2021.
Jonathan has made no other calls on ADAP in the last 4 months.
There is 1 other peer that has a rating on ADAP. Out of the 1 peers that are also analyzing ADAP, 0 agree with Jonathan's Rating of Hold.
This is the rating of the analyst that currently disagrees with Jonathan
- Peter Lawson of "Barclays" Initiated at Sell and Held Target at $4 on, Friday, May 28th, 2021
